Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NATCO PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATCO PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
NATCO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 847 | 315 | - | |
Low | Rs | 502 | 228 | - | |
Sales per share (Unadj.) | Rs | 148.4 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | 39.2 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | 48.2 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 5.50 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 267.1 | 73.6 | - | |
Shares outstanding (eoy) | m | 182.47 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.5 | 2.9 | 157.1% | |
Avg P/E ratio | x | 17.2 | -11.5 | -149.8% | |
P/CF ratio (eoy) | x | 14.0 | -13.9 | -101.0% | |
Price / Book Value ratio | x | 2.5 | 3.7 | 68.5% | |
Dividend payout | % | 14.0 | 0 | - | |
Avg Mkt Cap | Rs m | 123,049 | 45,814 | 268.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 4,867 | 2,875 | 169.3% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,071 | 15,834 | 171.0% | |
Other income | Rs m | 1,285 | 111 | 1,158.9% | |
Total revenues | Rs m | 28,356 | 15,945 | 177.8% | |
Gross profit | Rs m | 9,117 | -2,744 | -332.3% | |
Depreciation | Rs m | 1,638 | 683 | 239.7% | |
Interest | Rs m | 145 | 429 | 33.8% | |
Profit before tax | Rs m | 8,619 | -3,745 | -230.1% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,466 | 234 | 626.4% | |
Profit after tax | Rs m | 7,153 | -3,990 | -179.3% | |
Gross profit margin | % | 33.7 | -17.3 | -194.3% | |
Effective tax rate | % | 17.0 | -6.2 | -272.2% | |
Net profit margin | % | 26.4 | -25.2 | -104.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 30,003 | 11,597 | 258.7% | |
Current liabilities | Rs m | 6,831 | 6,525 | 104.7% | |
Net working cap to sales | % | 85.6 | 32.0 | 267.2% | |
Current ratio | x | 4.4 | 1.8 | 247.1% | |
Inventory Days | Days | 63 | 111 | 57.2% | |
Debtors Days | Days | 115 | 124 | 93.1% | |
Net fixed assets | Rs m | 26,571 | 6,760 | 393.1% | |
Share capital | Rs m | 365 | 74 | 496.5% | |
Net worth | Rs m | 48,738 | 12,428 | 392.2% | |
Long term debt | Rs m | 0 | 4,367 | 0.0% | |
Total assets | Rs m | 56,574 | 23,477 | 241.0% | |
Interest coverage | x | 60.4 | -7.7 | -781.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.7 | 70.9% | |
Return on assets | % | 12.9 | -15.2 | -85.1% | |
Return on equity | % | 14.7 | -32.1 | -45.7% | |
Return on capital | % | 18.0 | -19.8 | -90.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,491 | 1,352 | 628.2% | |
From Investments | Rs m | -4,771 | -415 | 1,149.7% | |
From Financial Activity | Rs m | -3,630 | 3,964 | -91.6% | |
Net Cashflow | Rs m | 208 | 4,900 | 4.2% |
Compare NATCO PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NATCO PHARMA With: SANOFI INDIA CHEMO PHARMA ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH LASA SUPERGENERICS
Indian share markets continued the momentum as the session progressed and ended the higher.